Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Core Points - Pfizer has agreed to pay $29 million to resolve a dispute with the U.S. Securities and Exchange Commission (SEC) related to a 2013 insider trading settlement involving billionaire Steven A. Cohen [1] Company Summary - The settlement amount of $29 million indicates Pfizer's willingness to resolve regulatory disputes without prolonged litigation [1] - This resolution may help Pfizer maintain its reputation and focus on core business operations, potentially impacting investor confidence positively [1] Industry Summary - The case highlights ongoing scrutiny and regulatory challenges faced by companies in the pharmaceutical industry regarding insider trading practices [1] - The resolution of such disputes is crucial for maintaining market integrity and investor trust in the pharmaceutical sector [1]